DK202586A - PARTICLES WITH THE IMMUNOGENIC PROPERTIES RESPONSIBLE FOR ANTIGEN HBS, VECTOR AND ANIMAL CELLS FOR PRODUCING SUCH PARTICLES AND USING THESE FOR THE PREPARATION OF MIXED VACCINES - Google Patents

PARTICLES WITH THE IMMUNOGENIC PROPERTIES RESPONSIBLE FOR ANTIGEN HBS, VECTOR AND ANIMAL CELLS FOR PRODUCING SUCH PARTICLES AND USING THESE FOR THE PREPARATION OF MIXED VACCINES Download PDF

Info

Publication number
DK202586A
DK202586A DK202586A DK202586A DK202586A DK 202586 A DK202586 A DK 202586A DK 202586 A DK202586 A DK 202586A DK 202586 A DK202586 A DK 202586A DK 202586 A DK202586 A DK 202586A
Authority
DK
Denmark
Prior art keywords
particles
vector
producing
preparation
animal cells
Prior art date
Application number
DK202586A
Other languages
Danish (da)
Other versions
DK166357C (en
DK202586D0 (en
DK166357B (en
Inventor
Francis Delpeyroux
Nicole Chenciner
Annick Lim
Yves Malpiece
Rolf Streeck
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of DK202586D0 publication Critical patent/DK202586D0/en
Publication of DK202586A publication Critical patent/DK202586A/en
Publication of DK166357B publication Critical patent/DK166357B/en
Application granted granted Critical
Publication of DK166357C publication Critical patent/DK166357C/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to particles possessing the essential features of particles based on HBs antigen, these particles being formed from a major polypeptide characteristic of the HBs antigen into which has been incorporated a foreign polypeptide sequence provided with an immunogenic site different from those normally borne by the S gene. The invention also relates to recombinant DNAs coding for the major polypeptide transformed in the manner described above, and to cell lines transformed by this recombinant DNA and capable, in particular when the foreign amino acid sequence contains not more than 16 amino acids, of being excreted into the culture medium of the abovementioned cell line.
DK202586A 1985-05-02 1986-05-02 PARTICLES WITH IMMUNOGENIC PROPERTIES RESPONSIBLE FOR THE HBS ANTIGEN AND VECTORS AND ANIMAL CELLS FOR PRODUCING SUCH PARTICLES DK166357C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8506708 1985-05-02
FR8506708A FR2581394B1 (en) 1985-05-02 1985-05-02 PARTICLES HAVING IMMUNOGENIC PROPERTIES OF THE HBS ANTIGEN AND CARRYING A FOREIGN ANTIGENIC SITE TO THE EPITOPES CARRIED BY THE HBS ANTIGEN, ANIMAL VECTORS AND CELLS FOR THE PRODUCTION OF SUCH PARTICLES AND COMPOSITIONS CONTAINING SUCH PARTICLES FOR THE PRODUCTION

Publications (4)

Publication Number Publication Date
DK202586D0 DK202586D0 (en) 1986-05-02
DK202586A true DK202586A (en) 1986-11-03
DK166357B DK166357B (en) 1993-04-13
DK166357C DK166357C (en) 1993-09-06

Family

ID=9318908

Family Applications (1)

Application Number Title Priority Date Filing Date
DK202586A DK166357C (en) 1985-05-02 1986-05-02 PARTICLES WITH IMMUNOGENIC PROPERTIES RESPONSIBLE FOR THE HBS ANTIGEN AND VECTORS AND ANIMAL CELLS FOR PRODUCING SUCH PARTICLES

Country Status (10)

Country Link
EP (1) EP0201416B1 (en)
JP (2) JPH088869B2 (en)
AT (1) ATE62508T1 (en)
CA (1) CA1282021C (en)
DE (1) DE3678609D1 (en)
DK (1) DK166357C (en)
ES (1) ES8703520A1 (en)
FR (1) FR2581394B1 (en)
GR (1) GR861141B (en)
PT (1) PT82500B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0278940A3 (en) * 1987-01-30 1988-12-07 Smithkline Biologicals S.A. Hepatitis b virus surface antigens and hybrid antigens containing them
EP0300213A1 (en) * 1987-06-22 1989-01-25 Hexal-Pharma Gentechnik GmbH & Co. KG Hepatitis a viral peptide particle immunogens
FR2635532B1 (en) * 1988-07-29 1992-05-22 Pasteur Institut HYBRID RECOMBINANT HBSAG PARTICLES: MORPHOLOGICAL CHARACTERISTICS OF THE HBSAG ANTIGEN CONTAINING 1 IMMUNOGENIC SEQUENCE INDUCING NEUTRALIZING ANTIBODIES DIRECTED AGAINST HIV OR LIKELY TO BE RECOGNIZED BY SUCH ANTIBODIES; NUCLEOTIDE SEQUENCES ENCODING FOR SUCH PARTICLES; VACCINES CONTAINING THEM
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
US6740323B1 (en) 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
EP1233783B9 (en) * 1999-11-24 2006-03-15 Chiron Corporation Hbv/hcv virus-like particle
JP4085231B2 (en) * 2000-02-28 2008-05-14 株式会社ビークル Protein hollow nanoparticles, substance carrier using the same, and method for introducing substance into cells
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
JP2003286189A (en) * 2002-03-29 2003-10-07 Japan Science & Technology Corp Medicament obtained by together fusing hollow nano- particle forming protein with cell-transducing substance for treating disease
JP2003286199A (en) * 2002-03-29 2003-10-07 Japan Science & Technology Corp Therapeutic medicine for hepatic disease using protein hollow nanoparticle
JP2003286198A (en) * 2002-03-29 2003-10-07 Japan Science & Technology Corp Therapeutic medicine using protein hollow nanoparticle expression growth factor, and the like
EP1541135A4 (en) * 2002-06-28 2005-09-28 Japan Science & Tech Agency Hollow nanoparticle having modified cysteine residue and drug with the use thereof
DE602004008582T2 (en) * 2003-02-17 2008-05-21 Peter Burkhard PEPTIDIC NANOTEHICLES AS DRUG DISPENSING AND ANTIGEN DISPLAY SYSTEMS
KR20050115913A (en) 2003-03-26 2005-12-08 사이토스 바이오테크놀로지 아게 Melan-a peptide analogue-virus-like-particle conjugates
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
RU2014106936A (en) 2011-10-12 2015-11-20 Альфа-О Пептидс Аг SELF-ASSEMBLY PEPTIDE NANOPARTICLES AS VACCINES AGAINST NORVIRAL INFECTION
EP2940133A4 (en) 2012-12-25 2016-07-06 Chemo Sero Therapeut Res Inst Vaccine for hpv infection and/or hepatitis b containing hpv/hbs chimeric protein as active ingredient
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
WO2018154010A1 (en) 2017-02-23 2018-08-30 Alpha-O Peptides Ag Self-assembling protein nanoparticles encapsulating immunostimulatory nucleid acids
JP2020514382A (en) 2017-03-23 2020-05-21 アルファ−オ ペプティデス アクツィエンゲゼルシャフト Self-assembling protein nanoparticles with built-in 6-helix bundle protein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415491A (en) * 1980-01-14 1983-11-15 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
FR2532850B1 (en) * 1982-09-15 1985-12-20 Pasteur Institut IMMUNOGENIC CONJUGATES BETWEEN A HAPTENA AND A CARRIER MOLECULE DERIVED FROM A TOXIN, THE VACCINES CONTAINING THEM AND PROCESS FOR OBTAINING THEM
US4483793A (en) * 1982-10-04 1984-11-20 The Regents Of The University Of California Dimeric oligopeptides as heptenic epitopic sites for hepatitis
FR2550203B1 (en) * 1983-08-01 1985-11-22 Anvar SYNTHETIC IMMUNOGENIC PEPTIDES CARRYING A CHARACTERISTIC EPITOPE OF THE HEPATITIS B VIRUS SURFACE ANTIGEN AND COMPOSITIONS CONTAINING THEM
FR2569984B1 (en) * 1984-09-12 1987-08-14 Anvar SYNTHETIC MOLECULE CONTAINING A PLURALITY OF SEPARATE EPITOPES, PROCESS FOR OBTAINING SAME AND APPLICATION TO THE PRODUCTION OF POLYVACCINES

Also Published As

Publication number Publication date
DK166357C (en) 1993-09-06
DK202586D0 (en) 1986-05-02
FR2581394A1 (en) 1986-11-07
PT82500A (en) 1986-06-01
JPH088869B2 (en) 1996-01-31
JPH08198897A (en) 1996-08-06
PT82500B (en) 1989-05-12
ATE62508T1 (en) 1991-04-15
DE3678609D1 (en) 1991-05-16
CA1282021C (en) 1991-03-26
JPS61258000A (en) 1986-11-15
EP0201416A1 (en) 1986-11-12
GR861141B (en) 1986-08-21
ES8703520A1 (en) 1987-03-01
DK166357B (en) 1993-04-13
ES555124A0 (en) 1987-03-01
FR2581394B1 (en) 1988-08-05
EP0201416B1 (en) 1991-04-10

Similar Documents

Publication Publication Date Title
DK202586A (en) PARTICLES WITH THE IMMUNOGENIC PROPERTIES RESPONSIBLE FOR ANTIGEN HBS, VECTOR AND ANIMAL CELLS FOR PRODUCING SUCH PARTICLES AND USING THESE FOR THE PREPARATION OF MIXED VACCINES
IL87737A0 (en) Method for culturing recombinant cells
CA2020668A1 (en) Fused or hybrid protein comprising viral antigen and lymphokine
AU3192889A (en) T cell activation markers
DE3584866D1 (en) HYBRID PARTICLE IMMUNOGENES.
DK127786D0 (en) METHOD FOR MANUFACTURING TGF-BETA, DNA AND MRNA CODING TGF-BETA, AND REPLICABLE VECTORS INCLUDING THE DNA AND HOST CELL-CONTAINING VECTORS
PT83065A (en) FUSION PROTEINS PROCESS FOR THEIR MANUFACTURE AND ITS USE
WO2000034474A3 (en) Growth factor homolog zvegf3
GB2182949B (en) Monoclonal antibodies and antigens for human non-small cell lung carcinomas
GR3007909T3 (en)
DE3750348D1 (en) Process for the preparation of peptides, recombinant plasmid to be used for this and myeloma cells transformed with this plasmid.
WO2003097814A3 (en) Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins
AU1321988A (en) The cloning of malaria-specific dna sequences: isolation of the gene for the 140 kd protein
EP0949333A4 (en) Mutant measles virus antigens and genes encoding the same
PT89511A (en) New growth regulating proteins designated amphiregulin - inhibiting tumours but stimulating some normal cells, also new precursor protein, encoding nucleic acid sequences and antibodies
EP0953642A4 (en) Antigenic protein originating in infectious laryngotracheitis virus

Legal Events

Date Code Title Description
PBP Patent lapsed